Lenalidomide for Refractory Cutaneous Manifestations of Pediatric Systemic Lupus Erythematosus

The study reviewed the use of lenalidomide for treating refractory cutaneous manifestations in 10 adolescents with pediatric systemic lupus erythematosus (pSLE). Within 6 months, all patients experienced complete or near resolution of their skin conditions, and prednisone doses were significantly reduced. Lenalidomide was well-tolerated without significant changes in white blood cell counts or other adverse effects. The findings suggested lenalidomide could be an effective and safe treatment for dermatologic conditions in pSLE, though further prospective studies were recommended.